Zepbound vs Wegovy: Which Weight-Loss Injection Is Better?
Zepbound and Wegovy are FDA-approved chronic weight-management injections. Zepbound generally produced greater average weight reduction, while Wegovy has product-specific cardiovascular evidence and an oral formulation pathway.
Comparison at a glance
| Feature | Wegovy | Zepbound |
|---|---|---|
| Ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 | GIP/GLP-1 |
| Schedule | Weekly injection | Weekly injection |
| Additional consideration | Product-specific cardiovascular indication | Moderate-to-severe OSA indication in defined adults with obesity |
| Choice depends on | Safety, response, form preference, access | Safety, desired benefit, OSA, access |
Medical conditions can change the choice
Established cardiovascular disease, diabetes treatment, diabetic retinopathy, sleep apnea, gastrointestinal disease, gallbladder history, pregnancy plans and other medications all matter. Product labels share some class warnings but are not identical.
Why W8MD does not automatically choose the strongest drug
The highest dose or greatest trial average may not provide the best balance of tolerability, affordability and long-term adherence. A patient who tolerates Wegovy well and has stable coverage may not benefit from switching merely because another product ranked higher in a study.
What to expect from a W8MD medication evaluation
The first step is not choosing a brand from an advertisement. W8MD reviews weight history, previous diets and prescriptions, medication allergies, blood pressure, pulse, sleep symptoms, glucose status, relevant laboratory results, cardiovascular history, gastrointestinal symptoms, kidney and liver concerns, pregnancy plans and current medicines. This helps identify contraindications and realistic alternatives.
The treatment plan can include a lower-cost traditional prescription, an FDA-approved incretin medicine, structured nutrition, meal replacements, a medically supervised very-low-calorie diet for selected patients, home sleep-apnea testing or a combination of services. Follow-up assesses appetite response, adverse effects, hydration, protein intake, bowel symptoms, blood pressure, muscle preservation and progress toward health-centered goals. A dose is not increased simply because a calendar date arrives.
Affordable W8MD treatment pathways
Semaglutide
From $29.99/week when insurance is accepted for qualifying visits. Self-pay pathways start from $59.99/week.
Tirzepatide
From $45/week when insurance is accepted for qualifying visits. Self-pay pathways start from $69.99/week.
Traditional prescriptions
Phentermine, topiramate, Qsymia, Contrave, diethylpropion, phendimetrazine and orlistat may be considered when clinically appropriate.
Pricing notice: Starting prices are not guaranteed for every patient or dose. Visit, medication, laboratory, supply, shipping, copay, deductible and dose costs may be separate. Insurance coverage of a visit does not guarantee pharmacy coverage.
Medication safety and supervision
Prescription obesity treatment requires an individualized evaluation. Common considerations include pregnancy, cardiovascular disease, blood pressure, kidney and liver health, gastrointestinal disease, gallbladder and pancreatic history, glaucoma, mental health, diabetes medicines, controlled-substance risk and drug interactions. Product-specific FDA labeling controls.
Frequently asked questions
Can I switch between them?
Sometimes, but there is no universal dose conversion. A prescriber must plan timing and escalation.
Which has an OSA indication?
Zepbound has an indication for defined adults with obesity and moderate-to-severe OSA.
Which is safer?
Safety depends on the patient; neither is universally safer.
Related Philadelphia and W8MD resources
Philadelphia services
WikiMD encyclopedia
How W8MD Philadelphia can help
W8MD physicians have more than 20 years of clinical experience and compare medical conditions, contraindications, previous attempts, appetite patterns, sleep, cultural food preferences, insurance coverage, patient preferences and long-term cost. Care can include medication, structured nutrition, a medically supervised VLCD for selected patients, sleep-apnea evaluation, muscle-preservation planning and maintenance.
1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115
Phone: 215-676-2334
Serving Northeast Philadelphia, Bucks County, Montgomery County, Delaware County, nearby Pennsylvania communities and South Jersey, subject to clinical and licensure requirements.
Contact W8MD Philadelphia
Use this form for nonurgent appointment and service questions.